Danielle MacNeil

London Health Sciences Centre

Papers

1

Total Citations

15

H-Index

1

About

Danielle MacNeil is a leading clinician-scientist whose research focuses on head and neck squamous cell carcinoma (HNSCC), with a particular emphasis on the distinct biology of human papillomavirus (HPV)-positive and HPV-negative disease. Her major contributions include pioneering high-throughput drug screening approaches to identify therapeutic agents with preferential activity based on HPV status. In her highly cited 2018 work, MacNeil and her team systematically tested a large panel of compounds against HNSCC cell lines, revealing that HPV-positive and HPV-negative tumors respond differently to existing drugs—a finding that has significant implications for personalized treatment strategies. This study, which has garnered 15 citations, exemplifies her commitment to translating laboratory discoveries into clinically actionable insights. MacNeil’s work bridges oncology, virology, and precision medicine, and she is recognized for her collaborative efforts in large-scale functional genomics and drug repurposing studies. Her research continues to shape how clinicians approach treatment selection for patients with head and neck cancers, offering new hope for improved outcomes through biomarker-driven therapy.

Research Focus

Key Achievements

1
H-Index
1
Papers
15
Total Citations
15
Avg Citations/Paper
🏆 Most Cited Paper
High-throughput testing in head and neck squamous cell carcinoma identifies agents with preferential activity in human papillomavirus-positive or negative cell lines
15 citations · 2018
📈 Most Prolific Year: 2018 (1 Papers)
🤝 Key Collaborators: 16
🏛 Institutions: London Health Sciences Centre

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago